

Juan J GÃ³mez-Reino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/109904/publications.pdf>

Version: 2024-02-01

237
papers

29,652
citations

8208

78
h-index

5739

167
g-index

243
all docs

243
docs citations

243
times ranked

25087
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	0.9	14
2	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001486.	1.8	24
3	Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. <i>Clinical Rheumatology</i> , 2021, 40, 3979-3988.	1.0	8
4	Long-term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , 2020, 2, 459-470.	0.9	12
5	Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1226-1237.	1.6	5
6	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 543-554.	0.9	7
7	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , 2020, 93, 100601.	0.5	10
8	Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 988-990.	0.5	66
9	Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. <i>Arthritis Research and Therapy</i> , 2020, 22, 143.	1.6	12
10	Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2020, , 179-203.	0.1	0
11	The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs. <i>Pharmacological Research</i> , 2019, 148, 104410.	3.1	8
12	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.5	58
13	Visfatin as a therapeutic target for rheumatoid arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 607-618.	1.5	25
14	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. <i>PLoS ONE</i> , 2019, 14, e0213073.	1.1	19
15	Abatacept for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 319-326.	1.3	34
16	Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. <i>Rheumatology International</i> , 2019, 39, 509-515.	1.5	28
17	Specific Association of HLA â€“ DRB 1*03 With Antiâ€“Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 331-339.	2.9	13
18	Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 690-698.	0.5	76

#	ARTICLE	IF	CITATIONS
19	Spanish transcultural adaptation and validation of the English version of the compliance questionnaire in rheumatology. <i>Rheumatology International</i> , 2018, 38, 467-472.	1.5	8
20	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.	1.8	20
21	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0196793.	1.1	13
22	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , 2018, 391, 2213-2224.	6.3	159
23	Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. <i>American Journal of Ophthalmology</i> , 2018, 195, 181-190.	1.7	177
24	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. <i>RMD Open</i> , 2018, 4, e000669.	1.8	31
25	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2018, 8, 7342.	1.6	18
26	166-Long-term (156-week) improvements in dactylitis and enthesitis with apremilast in psoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database. <i>Rheumatology</i> , 2018, 57, .	0.9	0
27	Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 1167-1172.	1.0	7
28	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017, 44, 162-169.	1.0	17
29	Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 149-156.	1.6	76
30	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
31	Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naïve or Free of Methotrexate for 6 Months: the AMBITION Study. <i>Journal of Rheumatology</i> , 2017, 44, 142-146.	1.0	27
32	Leptin in the interplay of inflammation, metabolism and immune system disorders. <i>Nature Reviews Rheumatology</i> , 2017, 13, 100-109.	3.5	371
33	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1598-1602.	0.5	54
34	Adipokines induce pro-inflammatory factors in activated Cd4+ T cells from osteoarthritis patient. <i>Journal of Orthopaedic Research</i> , 2017, 35, 1299-1303.	1.2	30
35	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	2.9	189
36	Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. <i>PLoS ONE</i> , 2017, 12, e0180144.	1.1	21

#	ARTICLE	IF	CITATIONS
37	Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. <i>Rheumatology</i> , 2016, 55, kev374.	0.9	95
38	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1133-1138.	0.5	186
39	The NICE position on indications for biologics and biosimilars. <i>Nature Reviews Rheumatology</i> , 2016, 12, 255-256.	3.5	2
40	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	0.9	22
41	Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. <i>Rheumatology International</i> , 2016, 36, 1043-1063.	1.5	36
42	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	1.6	37
43	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.5	275
44	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
45	The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 687-695.	0.5	166
46	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. <i>PLoS ONE</i> , 2016, 11, e0153140.	1.1	19
47	Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies. <i>PLoS ONE</i> , 2016, 11, e0161141.	1.1	32
48	Specific premature epigenetic aging of cartilage in osteoarthritis. <i>Aging</i> , 2016, 8, 2222-2231.	1.4	38
49	Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 362.	1.6	181
50	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015, 17, 157.	1.6	37
51	Rheumatoid arthritis response to treatment across IgG1 allotype " anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	1.6	9
52	Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. <i>Arthritis Research and Therapy</i> , 2015, 17, 233.	1.6	119
53	SERPINE2 Inhibits IL-1 β -Induced MMP-13 Expression in Human Chondrocytes: Involvement of ERK/NF- κ B/AP-1 Pathways. <i>PLoS ONE</i> , 2015, 10, e0135979.	1.1	42
54	Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 479-488.	1.0	122

#	ARTICLE	IF	CITATIONS
55	Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. <i>RMD Open</i> , 2015, 1, e000017-e000017.	1.8	86
56	The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. <i>Biomarkers</i> , 2015, 20, 565-571.	0.9	188
57	High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2015, 94, e0924.	0.4	64
58	Apremilast for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1281-1290.	1.3	11
59	New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history. <i>Drug Discovery Today</i> , 2015, 20, 406-410.	3.2	28
60	Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 564-568.	0.5	39
61	Predictors of treatment failure and mortality in native septic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1961-1967.	1.0	38
62	Effect of lysophosphatidic acid receptor inhibition on bone changes in ovariectomized mice. <i>Journal of Bone and Mineral Metabolism</i> , 2015, 33, 383-391.	1.3	5
63	Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain. <i>ReumatologÃ­a ClÃ­nica (English Edition)</i> , 2015, 11, 144-150.	0.2	2
64	Eficacia y seguridad de golimumab aÃ±adido a fÃ¡rmacos antirreumÃ¡ticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en EspaÃ±a. <i>ReumatologÃ­a ClÃ­nica</i> , 2015, 11, 144-150.	0.2	3
65	<i>FCGR</i> polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 333-345.	0.6	21
66	Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-analysis. <i>Arthritis and Rheumatology</i> , 2015, 67, 117-127.	2.9	125
67	Analysis of Infections and All-cause Mortality in Phase II, Phase III, and Long-term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2924-2937.	2.9	143
68	Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study. <i>Arthritis Research and Therapy</i> , 2014, 16, 436.	1.6	5
69	Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. <i>Rheumatology</i> , 2014, 53, 1872-1885.	0.9	132
70	Assessment of Osteoarthritis Candidate Genes in a Meta-analysis of Nine Genome-wide Association Studies. <i>Arthritis and Rheumatology</i> , 2014, 66, 940-949.	2.9	108
71	NUCB2/nesfatin-1: A new adipokine expressed in human and murine chondrocytes with pro-inflammatory properties, an in vitro study. <i>Journal of Orthopaedic Research</i> , 2014, 32, 653-660.	1.2	43
72	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014, 16, R66.	1.6	25

#	ARTICLE	IF	CITATIONS
73	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 238-245.	0.7	32
74	Adipokines, Metabolic Syndrome and Rheumatic Diseases. <i>Journal of Immunology Research</i> , 2014, 2014, 1-14.	0.9	130
75	Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 414.	1.6	23
76	Potential role of apremilast for the treatment of psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 259-266.	0.3	0
77	Health-related quality of life in psoriatic arthritis patients in Spain. <i>ReumatologÃ­a ClÃ­nica</i> , 2014, 10, 25-31.	0.2	15
78	Documento prÃ¡ctico para el uso de abatacept subcutÃ¡neo. <i>ReumatologÃ­a ClÃ­nica</i> , 2014, 10, 218-226.	0.2	2
79	Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies. <i>Joint Bone Spine</i> , 2014, 81, 41-50.	0.8	22
80	Adipokines as drug targets in joint and bone disease. <i>Drug Discovery Today</i> , 2014, 19, 241-258.	3.2	53
81	Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. <i>Rheumatology International</i> , 2014, 34, 1059-1063.	1.5	19
82	Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. <i>Rheumatology</i> , 2014, 53, 834-838.	0.9	30
83	Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 871-882.	0.5	49
84	Differential expression of adipokines in infrapatellar fat pad (IPFP) and synovium of osteoarthritis patients and healthy individuals. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 631-633.	0.5	59
85	Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 945-957.	2.5	11
86	Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2014, 16, R128.	1.6	11
87	Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 298-305.	0.5	47
88	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1020-1026.	0.5	372
89	An update on leptin as immunomodulator. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1165-1170.	1.3	45
90	Predictors of Response to TNF Antagonists. <i>Current Pharmaceutical Design</i> , 2014, 21, 221-232.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions. <i>JAMA Internal Medicine</i> , 2013, 173, 1416.	2.6	129
92	El uso de abatacept en artritis reumatoide: revisi3n de la evidencia y recomendaciones. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 5-17.	0.2	18
93	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 542-542.	6.7	1
94	Le facteur rhumatoÃde ne semble pas prÃdire la rÃponse aux anti-TNF Â dans la polyarthrite rhumatoÃdeÂ: expÃrience de trois centres. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 527-528.	0.0	1
95	Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: Three centers experience. <i>Joint Bone Spine</i> , 2013, 80, 438-440.	0.8	4
96	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	1.0	108
97	Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 9-17.	1.6	76
98	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 583-589.	0.5	80
99	The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 315-326.	0.3	5
100	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 83-88.	0.5	51
101	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
102	Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1830-1835.	0.5	143
103	Nitric oxide boosts TLR4 mediated lipocalin 2 expression in chondrocytes. <i>Journal of Orthopaedic Research</i> , 2013, 31, 1046-1052.	1.2	25
104	Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 2024-2031.	1.5	52
105	Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies. <i>Arthritis Research and Therapy</i> , 2013, 15, R82.	1.6	1
106	Ultrasonographic Assessment of Enthesitis in HLA-B27 Positive Patients with Rheumatoid Arthritis, a Matched Case-Only Study. <i>PLoS ONE</i> , 2013, 8, e58616.	1.1	13
107	Adipokines, Molecular Players at the Crossroad Between Inflammation and Oxidative Stress: Role in Arthropathies. , 2013, , 67-88.		0
108	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 374-377.	0.5	64

#	ARTICLE	IF	CITATIONS
109	Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2012, 2012, 1-14.	1.4	54
110	Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1289-1296.	0.5	43
111	Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1861-1864.	0.5	74
112	Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 2012, 77, 372-382.	1.2	45
113	Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 382-385.	0.5	61
114	Association of anti-citrullinated vimentin and anti-citrullinated Î±-enolase antibodies with subsets of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3102-3110.	6.7	21
115	Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 89-103.	1.6	59
116	Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1Î± and IL-6 in J774 macrophages and in ATDC5 chondrocytes. <i>Life Sciences</i> , 2012, 91, 1229-1235.	2.0	80
117	Association of a BMP5 microsatellite with knee osteoarthritis: case-control study. <i>Arthritis Research and Therapy</i> , 2012, 14, R257.	1.6	5
118	Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. <i>Arthritis Research and Therapy</i> , 2012, 14, R94.	1.6	8
119	Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study. <i>PLoS ONE</i> , 2012, 7, e45356.	1.1	28
120	Variants Within STAT Genes Reveal Association with Anticitrullinated Protein Antibody-negative Rheumatoid Arthritis in 2 European Populations. <i>Journal of Rheumatology</i> , 2012, 39, 1509-1516.	1.0	23
121	Genetic risk load and age at symptom onset of knee osteoarthritis. <i>Journal of Orthopaedic Research</i> , 2012, 30, 905-909.	1.2	8
122	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. <i>Arthritis and Rheumatism</i> , 2012, 64, 970-981.	6.7	293
123	Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2504-2517.	6.7	171
124	Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to tumor necrosis factor-induced apoptosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2460-2470.	6.7	28
125	Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, v31-v37.	0.9	27
126	Adiponectin and Leptin Induce VCAM-1 Expression in Human and Murine Chondrocytes. <i>PLoS ONE</i> , 2012, 7, e52533.	1.1	84

#	ARTICLE	IF	CITATIONS
127	Infections in Patients with Rheumatic Diseases Treated with TNF Antagonists. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1418-1425.	0.9	6
128	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A13.2-A14.	0.5	2
129	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1575-1580.	0.5	188
130	Consensus on the use of Rituximab in Rheumatoid Arthritis. A document with evidence based recommendations. <i>ReumatologÃ­a ClÃ­nica (English Edition)</i> , 2011, 7, 30-44.	0.2	0
131	What's new in our understanding of the role of adipokines in rheumatic diseases?. <i>Nature Reviews Rheumatology</i> , 2011, 7, 528-536.	3.5	254
132	Adiponectin and leptin increase IL-8 production in human chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2052-2054.	0.5	75
133	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
134	Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines. <i>Arthritis Research and Therapy</i> , 2011, 13, R80.	1.6	12
135	Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 864-867.	0.5	119
136	Beyond Fat Mass: Exploring the Role of Adipokines in Rheumatic Diseases. <i>Scientific World Journal</i> , The, 2011, 11, 1932-1947.	0.8	56
137	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 330-337.	1.6	49
138	Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 71-80.	1.6	94
139	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 524-533.	1.6	60
140	Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. <i>BioFactors</i> , 2011, 37, 413-420.	2.6	162
141	Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1949-1956.	0.5	71
142	Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 153.	0.8	128
143	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
144	Particular association of clinical and genetic features with autoimmunity to citrullinated Î±-enolase in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 654-661.	6.7	36

#	ARTICLE	IF	CITATIONS
145	Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. <i>Rheumatology</i> , 2011, 50, 1999-2004.	0.9	44
146	Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology</i> , 2011, 50, 85-92.	0.9	36
147	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.5	71
148	The risk of tuberculosis in patients treated with TNF antagonists. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 329-340.	1.3	46
149	Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 551-559.	0.5	108
150	Association of Systemic Lupus Erythematosus Clinical Features with European Population Genetic Substructure. <i>PLoS ONE</i> , 2011, 6, e29033.	1.1	14
151	Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 88-96.	0.5	687
152	Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis. <i>Science Translational Medicine</i> , 2010, 2, 52ra72.	5.8	774
153	Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line. <i>Arthritis and Rheumatism</i> , 2010, 62, 1675-1682.	6.7	88
154	Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis. <i>Journal of International Medical Research</i> , 2010, 38, 1213-1224.	0.4	128
155	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1751-1755.	0.5	96
156	CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2013-2016.	0.5	56
157	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
158	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	3.1	444
159	Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1010-1014.	0.5	149
160	At the crossroad between immunity and metabolism: focus on leptin. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 801-808.	1.3	71
161	Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. <i>Arthritis Research and Therapy</i> , 2010, 12, R224.	1.6	48
162	Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. <i>Arthritis Research and Therapy</i> , 2010, 12, R72.	1.6	36

#	ARTICLE	IF	CITATIONS
163	Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. <i>Arthritis Research and Therapy</i> , 2010, 12, R33.	1.6	51
164	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
165	New Sequence Variants in HLA Class II/III Region Associated with Susceptibility to Knee Osteoarthritis Identified by Genome-Wide Association Study. <i>PLoS ONE</i> , 2010, 5, e9723.	1.1	96
166	Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 583-591.	1.5	13
167	Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations. <i>Human Molecular Genetics</i> , 2009, 18, 1518-1523.	1.4	50
168	Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1870-1877.	0.5	301
169	Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. <i>Journal of Molecular Endocrinology</i> , 2009, 43, 11-18.	1.1	83
170	Adipokines as novel modulators of lipid metabolism. <i>Trends in Biochemical Sciences</i> , 2009, 34, 500-510.	3.7	173
171	DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 91.	0.8	26
172	Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 976-986.	6.7	547
173	Expression and modulation of ghrelin <i>O</i> -acyltransferase in cultured chondrocytes. <i>Arthritis and Rheumatism</i> , 2009, 60, 1704-1709.	6.7	39
174	Large-scale analysis of association between <i>GDF5</i> and <i>FRZB</i> variants and osteoarthritis of the hip, knee, and hand. <i>Arthritis and Rheumatism</i> , 2009, 60, 1710-1721.	6.7	181
175	Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. <i>Arthritis and Rheumatism</i> , 2009, 60, 2558-2564.	6.7	55
176	Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA. <i>Journal of Rheumatology</i> , 2009, 36, 1590-1595.	1.0	15
177	Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. <i>Arthritis Research and Therapy</i> , 2009, 11, R69.	1.6	131
178	Analysis of TNFAIP3, a feedback inhibitor of nuclear factor- κ B and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. <i>Arthritis Research and Therapy</i> , 2009, 11, R42.	1.6	51
179	Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage. <i>BMC Molecular Biology</i> , 2008, 9, 17.	3.0	73
180	Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 435-441.	6.7	38

#	ARTICLE	IF	CITATIONS
181	Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1264-1274.	6.7	85
182	A broad analysis of IL1 polymorphism and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1947-1957.	6.7	31
183	Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2968-2980.	6.7	752
184	Leptin beyond body weight regulation—Current concepts concerning its role in immune function and inflammation. <i>Cellular Immunology</i> , 2008, 252, 139-145.	1.4	168
185	A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2008, 16, 1101-1109.	0.6	241
186	Poly(ADP-ribose) polymerase suppression protects rheumatoid synovial fibroblasts from Fas-induced apoptosis. <i>Rheumatology</i> , 2008, 48, 483-489.	0.9	9
187	Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1399-1400.	0.5	9
188	An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. <i>Human Molecular Genetics</i> , 2007, 16, 2226-2232.	1.4	180
189	All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 880-885.	0.5	196
190	The emerging role of adipokines as mediators of inflammation and immune responses. <i>Cytokine and Growth Factor Reviews</i> , 2007, 18, 313-325.	3.2	316
191	Adipokines as emerging mediators of immune response and inflammation. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 716-724.	3.2	457
192	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. <i>Arthritis and Rheumatism</i> , 2007, 57, 756-761.	6.7	378
193	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. <i>Rheumatology International</i> , 2007, 27, 793-806.	1.5	85
194	Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. <i>Arthritis Research and Therapy</i> , 2006, 8, R72.	1.6	167
195	Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians. <i>Arthritis Research and Therapy</i> , 2006, 8, R55.	1.6	58
196	Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. <i>Arthritis Research and Therapy</i> , 2006, 8, R29.	1.6	250
197	Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. <i>Arthritis Research and Therapy</i> , 2006, 8, R1.	1.6	37
198	Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. <i>Arthritis Research and Therapy</i> , 2006, 8, R14.	1.6	31

#	ARTICLE	IF	CITATIONS
199	Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1198-1201.	0.5	437
200	Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 560-561.	0.5	13
201	Leptin: A metabolic hormone that functions like a proinflammatory adipokine. <i>Drug News and Perspectives</i> , 2006, 19, 21.	1.9	83
202	Ghrelin in the Local Regulation of Endocrine Glands. , 2006, , 869-875.		0
203	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , 2005, 52, 1766-1772.	6.7	612
204	Polymorphism of the interleukin-1 receptor antagonist gene: A factor in susceptibility to rheumatoid arthritis in a Spanish population. <i>Arthritis and Rheumatism</i> , 2005, 52, 3015-3019.	6.7	27
205	Ghrelin plasmatic levels in patients with fibromyalgia. <i>Rheumatology International</i> , 2005, 25, 6-8.	1.5	7
206	Ghrelin, the Same Peptide for Different Functions: Player or Bystander?. <i>Vitamins and Hormones</i> , 2005, 71, 405-432.	0.7	18
207	Leptin, from fat to inflammation: old questions and new insights. <i>FEBS Letters</i> , 2005, 579, 295-301.	1.3	337
208	A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 328-329.	6.7	40
209	Association of PDCD1 with susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2590-2597.	6.7	106
210	Novel DNASE I mutations related to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 4070-4071.	6.7	32
211	Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor. <i>Respiratory Medicine</i> , 2004, 98, 123-125.	1.3	17
212	Synergistic induction of nitric oxide synthase type II: In vitro effect of leptin and interferon- γ in human chondrocytes and ATDC5 chondrogenic cells. <i>Arthritis and Rheumatism</i> , 2003, 48, 404-409.	6.7	136
213	Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. <i>Arthritis and Rheumatism</i> , 2003, 48, 2122-2127.	6.7	889
214	Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. <i>FEBS Letters</i> , 2003, 552, 105-109.	1.3	129
215	Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. <i>Arthritis and Rheumatism</i> , 1999, 42, 989-992.	6.7	133
216	Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. , 1999, 188, 63-68.		64

#	ARTICLE	IF	CITATIONS
217	Internuclear ophthalmoplegia in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 179-186.	1.6	26
218	Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. <i>Lupus</i> , 1998, 7, 159-163.	0.8	60
219	Apoptosis and Proliferation of Fibroblasts During Postnatal Skin Development and Scleroderma in the Tight-skin Mouse. <i>Journal of Histochemistry and Cytochemistry</i> , 1997, 45, 711-719.	1.3	33
220	Inflammation and HIV infection: a friendly connection. <i>Lancet, The</i> , 1996, 348, S24.	6.3	1
221	Outcome of silent lupus nephritis. <i>Seminars in Arthritis and Rheumatism</i> , 1996, 26, 468-476.	1.6	60
222	Abnormal carnitine distribution in the muscles of patients with idiopathic inflammatory myopathy. <i>Arthritis and Rheumatism</i> , 1996, 39, 1869-1874.	6.7	10
223	Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. <i>Arthritis and Rheumatism</i> , 1996, 39, 2028-2034.	6.7	89
224	Invasive aspergillosis in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1995, 24, 304-314.	1.6	44
225	Autoantibodies in Sera from Patients with L-Tryptophan-Associated Eosinophilia-Myalgia Syndrome. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 115-119.	2.1	4
226	PULMONARY HYPERTENSION IN CONNECTIVE TISSUE DISEASES. <i>Rheumatology</i> , 1994, 33, 796-797.	0.9	1
227	Clonally expanded lymphocytes in the minor salivary glands of sjögren's syndrome patients without lymphoproliferative disease. <i>Arthritis and Rheumatism</i> , 1994, 37, 1441-1444.	6.7	44
228	Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. <i>Arthritis and Rheumatism</i> , 1994, 37, 1528-1533.	6.7	94
229	Nontropical pyomyositis in adults. <i>Seminars in Arthritis and Rheumatism</i> , 1994, 23, 396-405.	1.6	92
230	Differential contribution of C4 and HLA-DQ genes to systemic lupus erythematosus susceptibility. <i>Human Genetics</i> , 1993, 91, 579-584.	1.8	18
231	Factor B activation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1990, 33, 1598-1599.	6.7	3
232	Both HLA class II and class III DNA polymorphisms are linked to juvenile rheumatoid arthritis susceptibility. <i>Clinical Immunology and Immunopathology</i> , 1990, 56, 22-28.	2.1	22
233	Male lupus: Retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 18, 189-197.	1.6	69
234	An Eco RI polymorphic site in the human complement C4 gene distinguishes Juvenile Rheumatoid Arthritis (JRA) susceptibility-bearing haplotypes. <i>Molecular Immunology</i> , 1989, 26, 427-430.	1.0	8

#	ARTICLE	IF	CITATIONS
235	A review of peripheral tuberculous arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1988, 18, 142-149.	1.6	116
236	Bf polymorphisms in systemic lupus erythematosus patients of Spanish descent. <i>Arthritis and Rheumatism</i> , 1986, 29, 932-933.	6.7	7
237	Pseudoaneurysm of the popliteal artery as a complication of an osteochondroma. <i>Skeletal Radiology</i> , 1979, 4, 26-28.	1.2	15